anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses 9-substituted-2-amino-6-quanidyl purine compounds as well as a preparation method and application thereof. Through in vitro activity detection tests, 26 relevant compounds react with human acrosin with fertility activity, and the residual enzyme activity is detected by an improved Kennedy method. The 26 relevant compounds are compared with a classic acrosin inhibitor TLCK. Results show that all the tested compounds have inhibition activity on the human acrosin and have stronger inhibition activity than that of the positive control product TLCK. Researches verify that the compounds have strong antifertility activity and can be used for preparing antifertility drugs. New male contraceptive drugs are provided in clinic, and the compounds have greater application value. The invention provides the preparation method.
A cosmetic is prepd. by mixing hydrosoluble and liposoluble active substances extracted from embryonic nektons composed mainly of larval stage marine organisms, pref. a mixt. of 90% Clupeidae and 10% Crustacea, larvae, esp. 10% Copepoda from cultivated plankton with glycerine and/or lanolin with an excipient permitting transepidernal penetration, pref. active extracts are used in amt. 1-100 g per kg product. Embryonic nektons can be included in excipient cream after being finely ground, but without extraction. Prods. contain grown hormones, nutritive and oligo-elements beneficial in core of skin, mucous membrane and the scalp.
The invention belongs to the technical field of traditional Chinese medicine and particularly relates to mouthwash used during orthodontic treatment. The mouthwash is prepared from, by weight, 15-18 parts of aloes, 15-18 parts of green tea, 10-15 parts of cortex erythrinae, 3-8 parts of shinyleaf pricklyash roots, 1-3 parts of surfactant, 1-5 parts of sodium chloride and 100 parts of deionized water. The aloes are used for sterilization and inflammation prevention. The green tea is used for sterilization and bacterium inhibition. Cortex erythrinae is used for inhibiting ulcers. The shinyleaf pricklyash roots are used for detoxification and detumescence. The mouthwash can be used for cleaning the oral cavity, has the tooth-decay-prevention, hemostatic and antiphlogistic effects, improves the oral environment during orthodontic treatment of the oral cavity, and reduces the probability of oral complications.
Capsules for admin. through a normal inhaler, inhaler tube or nasal spray contain the active principle of one or more allergens diluted in one or more excipients which must be free from any bronchoconstrictive action and non-irritant to the nasal mucous membrane. - Capsules are used in hyposensitisation therapy, for both therapeutic and diagnostic purposes. They allow the allergen active principle to come into direct contact with the upper and lower respiratory systems without modification of its biological activity, and their use avoids the disadvantages of parenteral admin. or atomisation and inhalation of an aq. soln. of the allergen. EPAB- EP--67130 B An allergen dry powder compsn. comprising a mixt. of theactive principle of the allergen and one ofor more excipients, characterised in that the dilution of the active principle of the allergen in the excipient is uniform and homogeneous by wet or soln. mixing the active principle with the excipient. (5pp) GBAB- GB2099698 B Capsules for admin. through a normal inhaler, inhaler tube or nasal spray contain the active principle of one or more allergens diluted in one or more excipients which must be free from any bronchoconstrictive action and non-irritant to the nasal mucous membrane. - Capsules are used in hyposensitisation therapy, for both therapeutic and diagnostic purposes. They allow the allergen active principle to come into direct contact with the upper and lower respiratory systems without modification of its biological activity, and their use avoids the disadvantages of parenteral admin. or atomisation and inhalation of an aq. soln. of the allergen. (4pp) USAB- US4681752 A A telescoping two-piece hard gelatine capsule is perforated to emit powder through the holes and is administered through insertion in an inhaler, inhaler tube or nasal spray. Each capsule contains 40mg of a finely-divided freeze-dry anhydrous powder mixt., with particles 90% smaller than 10 microns and the remaining 10% smaller than 20 microns, of an active constituent of an allergan which is uniformly dispersed into at least one lactose, glucose or saccharose excipient which has no bronchoconstrictive or irritating action on the nasal mucous membrane. - The allergan is one of Dermatophagoides- pteronyssinus or -farinae (mites), Ambrosia elatior, Agrostis-maritama or stolonifera, Poa pratensis, Dactylis glomerata, Holcus lamatus, Phleum pratense, Phalaris canariensis, Lolium-perenne, or -multiflorum, Festuca-pratensis or ovina, Cynodon dactylon or Agarostis alba (pollens). The ratio of excipient to allergan used is 1:1 to 50,000:1.
505,983. Medicines ; cosmetics ; beverages ; making extracts. JOHNSON, G. W. (I. G. Farbenindustrie Akt.-Ges.) Nov. 17, 1937, Nos. 31629/37 and 33197/38. (Classes 14 (ii) and 81 (i)] (Also in Groups III, IV, and VIII] Preparations which are stable and homogeneously dilutable with water or aqueous media to form clear emulsions or solutions comprise organic compounds which are diffi. cultly soluble in water but soluble in organic. solvents to which water-soluble phosphatides such as lysolecithin and lysocephalin and synthetic products of analogous constitution are added. Suitable organic compounds include vegetable extracts obtained by organic solvents, essential oils, fats, and sterols and their derivatives. In the case of vegetable extracts, the phosphatides may be added to the plant to be extracted, to the extraction solvents, or to the final extracts, and extracts of camomile, peppermint, wormwood, juniper, &c. may be made and used in the production of liqueurs, wines, cosmetics and as additions to baths. Other phosphatides such as lecithin may be used in addition, and basic substances, e.g. alkali hydroxides or carbonates, ammonia or organic amines may also be added and in which case a smaller amount of the phosphatide may be used. According to examples : (1) dry sage crude extract is shaken with a dilute alcoholic solution of lysolecithin, and the solution may be diluted with water without separation; (2) sage oil dissolved in an alcoholic solution of lysolecithin gives a milky emulsion on dilution with water; (3) valerian crude extract is similarly treated; (4) chenopodium is dissolved in an alcoholic solution containing lecithin and lysolecithin, and forms a homogeneous emulsion on dilution; (5) dried elder flowers or sage leaves are extracted with an alcoholic solution of lysolecitliin. The addition of lysolecithin increases the yield of extract ; (6) artemisia absynthium is extracted hot with an alcoholic solution of lysolecithin. No separation occurs on dilution and the solution may be used in the production of wines and liqueurs (vermouth) ; (8) oleic acid triglyceride is dissolved in an alcoholic solution of lysolecithin or a similar synthetic phosphatide. The emulsion formed on dilution with water may be used for cosmetic purposes, or for treating leather. Specification 417,715 is referred to.
Patients receive nivolumab IV over 30 minutes on days -56, -42, -28, and -14 in the absence of disease progression or unacceptable toxicity. Patients then undergo nephrectomy or metastasectomy on day 0.
Participants will receive Nipocalimab at Week 0 (Baseline) and then every 2 weeks (Q2W) up to Week 50 during double-blind period. Participants on glucocorticoids (GC) at baseline will receive a stable dose of oral GC (prednisone or equivalent) from 4 weeks prior to the first administration of study intervention to Week 0. No changes in GC doses are allowed between Week 0 and Week 24. From Week 24 to Week 44, GC doses will be tapered. No changes to GC doses will be allowed from Week 44 to Week 52. Eligible participants will enter long-term extension (LTE) period and continue receiving Nipocalimab starting from Week 52 up to Week 98 and will be followed up to Week 106.
Background: Central nervous system (CNS) active medications have been consistently linked to falls in older people. However, few randomized trials have evaluated whether CNS-active medication reduction reduces falls and fall-related injuries. The objective of the Reducing CNS-active Medications to Prevent Falls and Injuries in Older Adults (STOP-FALLS) trial is to test the effectiveness of a health-system-embedded deprescribing intervention focused on CNS-active medications on the incidence of medically treated falls among community-dwelling older adults.

We will conduct a pragmatic, cluster-randomized, parallel-group, controlled clinical trial within Kaiser Permanente Washington to test the effectiveness of a 12-month deprescribing intervention consisting of: 1) an educational brochure and self-care handouts mailed to older adults prescribed one or more CNS-active medications (aged 60+: opioids, benzodiazepines and Z-drugs; aged 65+: skeletal muscle relaxants, tricyclic antidepressants, and antihistamines) and 2) decision support for their primary health care providers. Outcomes are examined over 18-26 months post-intervention. The primary outcome is first incident (post-baseline) medically treated fall as determined from health plan data. Our sample size calculations ensured at least 80% power to detect a 20% reduction in the rate of medically treated falls for participants receiving care within the intervention (n=9) versus usual care clinics (n=9) assuming 18 months of follow-up. Secondary outcomes include medication discontinuation or dose reduction of any target medications. Safety outcomes include serious adverse drug withdrawal events, unintentional overdose, and death. We will also examine medication signetur fields for attempts to decrease medications. We will report factors affecting implementation of the intervention.
F-18-F-DOPA i.v. one injection of a dose of up to 8.5 mCi (millicurie). Standard PET scanning started 60-90 minutes post injection.
The recommended dose of CAPRELSA is 300 mg taken orally once daily until disease progression or unacceptable toxicity occurs.

CAPRELSA may be taken with or without food.

Do not take a missed dose within 12 hours of the next dose.

Do not crush CAPRELSA tablets. The tablets can be dispersed in 2 ounces of water by stirring for approximately 10 minutes (will not completely dissolve). Do not use other liquids for dispersion. Swallow immediately after dispersion. Mix any remaining residue with 4 additional ounces of water and swallow. 

The dispersion can also be administered through nasogastric or gastrostomy tubes.
NEW MATERIAL:A peptide expressed by the formula (A and B represent Phe or Tyr; X and Y represent single bond, amino acid residue such as Asp or Glu, etc.; Z represents OH or amino group). USE:Useful for therapy of myasthenia gravis caused by an autoantibody to a nicotinic acetylcholine receptor (hereinafter referred to as 'receptor'). An adsorbing agent which effectively adsorbs and removes a human antibody to the receptor from a body is efficiently formed by immobilizing it on a carrier and heat-treating the peptide. PREPARATION:For example, a styrene-divinylbenzene copolymer bound with an acyloxy group formed by eliminating hydrogen atom from an alpha-carboxyl group contained in an amino acid corresponding to a C-terminus of the objective peptide is successively bound to corresponding amino acids toward the N- terminus of the objective peptide to form the peptide chain. Then the peptide chain is removed from the polymer and the protecting group thereof is eliminated.
The invention is directed to novel cells that are derived from human embryoid bodies. Such embryoid body-derived (EBD) cells are relatively uncommitted or progenitor (e.g., pluripotent) cells. EBD cells, while not immortal, display long-term proliferation in culture with a normal karyotype and can be cryopreserved and cloned. They can be efficiently transfected with retroviruses and lentivirus and genetically manipulated. Although they have a developmentally broad multilineage expression profile, they do not form tumors when injected into severe combined immunodeficiency (SCID) mice. As a result, EBD cells have a variety of uses, for example, in transplantation therapies.
RECONSTITUTED STOCK SOLUTION MUST BE TRANSFERRED AND FURTHER DILUTED FOR I.V. INFUSION

The 10 gram vial should be reconstituted with 95 mL of an appropriate IV diluent in a suitable work area such as a laminar flow hood. The resulting solution will contain approximately 100 mg/mL of ceftriaxone.

The container closure may be penetrated only one time, utilizing a suitable sterile transfer device or dispensing set which allows measured distribution of the contents. (A sterile substance which must be reconstituted prior to use may require a separate closure entry.) Use of this product is restricted to a suitable work area, such as a laminar flow hood.

The withdrawal of container contents should be accomplished without delay. However, should this not be possible, a maximum time of 4 hours from initial closure entry is permitted to complete fluid transfer operations. If reconstitution is necessary, this time limit should begin with the introduction of solvent or diluent into the Pharmacy Bulk Package.

Unused portions of solution held longer than the recommended time periods should be discarded.

Transfer individual dose to appropriate intravenous solutions as soon as possible following reconstitution of the bulk package. The stability of the solution that has been transferred into a container varies according to diluent, concentration and temperature (see Compatibility and Stability). Concentrations between 10 mg/mL and 40 mg/mL are recommended; however lower concentrations may be used if desired.
Determining the post-mortem interval (PMI) is one of forensic pathology's primary objectives and one of its most challenging tasks. Numerous studies have demonstrated the accuracy of histomorphology and immunohistochemical investigations in determining the time of death. Nevertheless, the skin, a robust and easy-to-remove tissue, has only been partially analyzed so far. By studying 20 adult male mice, we tried to determine whether post-mortem immunohistochemical detection in the skin of HMGB1 proteins and associated components (Beclin1 and RAGE) could be used for this purpose. We discovered that nuclear HMGB1 overexpression indicates that death occurred within the previous 12 h, nuclear HMGB1 negativization with high cytoplasmic HMGB1 intensity indicates that death occurred between 12 and 36 h earlier and cytoplasmic HMGB1 negativization indicates that more than 48 h have passed since death. RAGE and Beclin1 levels in the cytoplasm also decreased with time. The latter proteins' negativization might indicate that more than 24 and 36 h, respectively, have passed from the time of death. These indicators might potentially be helpful in forensic practice for determining the PMI using immunohistochemistry.
The present invention provides Jagged 1 and Frizzled 4 as cell surface markers for isolating human cardiomyogenic ventricular progenitor cells, in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Thus, the invention provides human ventricular progenitor (HVP) cells. The invention provides in vitro methods of the separation of Islet 1+ Jagged 1+ ventricular progenitor cells and/or Islet 1+/Frizzled 4+ ventricular progenitor cells and/or Islet 1+/Jagged 1+/Frizzled 4+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated Jagged 1+ and/or Frizzled 4+ventricular progenitor cells are also provided. Methods of in vivo use of Jagged 1+ and/or Frizzled 4+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the Jagged 1+ and/or Frizzled 4+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.
The present invention relates to a method for producing cytotoxic CD4 T cells, cytotoxic CD4 T cells produced by the method, and a use thereof. The method comprises a step of stimulating abdominal CD49d CD4^+ T cells by type I interferon. When the CD49d^(high) CD4^+ T cells of the present invention are stimulated by interferon β (IFNβ), cytotoxicity is exhibited, and MHCII of B1 cells are specifically recognized. Thus, the B1 cells are killed, and thus an effect of reducing the amount of natural IgM antibodies in mouse serum is excellent. Furthermore, the CD49d^(high) CD4^+ T cells also exhibit cytotoxicity to a B1 cell-derived lymphoma cell line WEHI-231, thereby significantly inhibiting lymphoma cells. Accordingly, the CD49d^(high) CD4^+ T cells stimulated by IFNβ can be effectively used for a pharmaceutical composition, immune cell therapeutic agent, or immunosuppressant agent for preventing or treating cytotoxic CD4 T cells or immune diseases.
This invention relates to a lockable, tamper resistant medication dispenser for medications with abuse potential and for monitoring medication compliance. The medication dispenser is programmed to dispense a specified dose of medication at a specified interval. The medication chamber of the dispenser is filled by the pharmacist and locked before being dispensed to the patient. This prevents direct access to the medication by the patient. The medication is dispensed to the patient dissolved in a large volume of liquid to prevent intravenous and intranasal abuse and diversion. The medication dispenser is equipped with biometric access control to prevent diversion. It can be equipped with a self destruct mechanism when tampered with and have the ability to record video of the actual ingestion of the medication infused liquid by the patient for subsequent analysis.
The invention belongs to the field of Chinese herbal medicines and particularly relates to a beverage containing a kidney-tonifying traditional Chinese medicine composition and a preparation method thereof. The method includes following steps: preparing peony flower extract and performing a crushing process, a pre-treating process, a drying process and a proportioning process. In the invention, white peony roots and cornua cervi pantotrichum are placed into a reaction kettle for reaction and finally are mixed with other components so that a kidney-tonifying function is greatly improved. In addition, the traditional Chinese medicine composition is quick in curative effects and enables a patient to feel a significant improvement just after 4-5 days. The beverage is good in mouthfeel, is portable and is easy to drink. By means of addition of the peony flower extract in the traditional Chinese medicine composition, a kidney-tonifying effect is greatly enhanced and absorption of medicine effects is promoted. All of the components in the traditional Chinese medicine composition are Chinese herbal medicines so that the traditional Chinese medicine composition is free of toxic and side effects and can be widely applied in people in different stages. Raw materials of the traditional Chinese medicine composition are easy to obtain. The traditional Chinese medicine composition is easy to prepare, is low in production cost, is wide in effects, is high in safety and is significant in benefit.
The healing of gastrointestinal anastomoses is a complex biological process influenced by numerous factors. Various strategies to support healing and prevent anastomotic leakage (AL) exist, encompassing preoperative, intraoperative and postoperative measures. Preoperative interventions aim to optimize the patient and the tissue environment, particularly the gut microbiome. Intraoperative measures are technical in nature and include the choice of surgical access, the anastomotic technique and anastomotic reinforcement. Various procedures of the intraoperative diagnostics enable identification of such anastomoses requiring additional protective measures. Recently, indocyanine green (ICG) fluoroscopy has become established for evaluation of tissue perfusion, while newer techniques such as spectral microscopy offer promising possibilities. Postoperative diagnostic methods aim to identify potential AL as early as possible to enable initiation of therapeutic steps even before the onset of symptoms. These procedures range from various imaging techniques to innovative bioresorbable, pH-sensitive implants for early AL detection. Due to the multifactorial genesis of AL and the diverse technical possibilities, no single method will become established for prevention of AL. Instead, a combination of measures will ultimately lead to optimal anastomotic healing. The use of artificial intelligence and analyses based on the data promises a better interpretation of the vast amount of data and therefore to be able to provide general recommendations.
Participants assigned to the control condition will not undergo any exercise manipulation during this 6 week period, and will be asked to continue their current activity levels and not engage in any additional exercise activity during the study period. Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.
The newly identified estrogen receptor, G protein-coupled receptor 30 (GPR30), is prevalent in the brain and has been shown to provide significant neuroprotection. Recent studies have linked ferroptosis, a newly characterized form of programmed cell death, closely with cerebral ischemia-reperfusion injury (CIRI), highlighting it as a major contributing factor. Consequently, our research aimed to explore the potential of GPR30 targeting in controlling neuronal ferroptosis and lessening CIRI impacts. Results indicated that GPR30 activation not only improved neurological outcomes and decreased infarct size in a mouse model but also lessened iron accumulation and malondialdehyde formation post-middle cerebral artery occlusion (MCAO). This protective effect extended to increased levels of Nrf2 and GPX4 proteins. Similar protective results were replicated in PC12 cells subjected to Oxygen Glucose Deprivation and Reoxygenation (OGD/R) using the GPR30-specific agonist G1. Importantly, inhibition of Nrf2 with ML385 curtailed the neuroprotective effects of GPR30 activation, suggesting that GPR30 mitigates CIRI primarily through inhibition of neuronal ferroptosis via upregulation of Nrf2 and GPX4.